OTLC
Oncotelic Therapeutics, Inc.
Next earnings Aug 11, 2026
$0.04
▼ -6.82%$0.04▼ -18.00%
over 1Y
L $0.03H $0.11
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-6.8%
1W-4.2%
1M-18.0%
3M+2.5%
YTD-48.8%
1Y-18.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Strong net margin (356114.0%); but revenue fell -96.0% YoY.
Revenue (FY2023) $70.0K · FY2023
The read
Middling fundamentals offset by an attractive price (~54583% below fair value) — worth a look on the value angle.
Oncotelic Therapeutics, Inc. shows $70.0K in FY2023 revenue (-96.0% YoY), a 356114.0% net margin, and 94.9% ROE.
Supporting the case: strong net margin (356114.0%); high return on equity (94.9%); conservative balance sheet (liabilities/equity 0.50x); undemanding valuation (P/E 0.1).
Is OTLC a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~0.04
- Short call 0 @ ~0.00 est
debit $4max +−$4max −$4
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $70.0K | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$9.13M | -$9.72M | -$6.65M | -$3.58M | -$3.19M |
| Net income | -$9.39M | $5.09M | -$7.90M | -$4.52M | $249M |
| Diluted EPS | -$0.03 | $0.01 | -$0.02 | -$0.01 | $0.59 |
| Net margin | — | — | -11290.1% | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$20.0M
EV / EBITDA—
EV / Sales285.6
EV / FCF—
P / FCF—
PEG (trailing)0.00
Earnings yield1404.8%
FCF yield-7.9%
Quality & risk
ROIC (est.)-0.9%
Free cash flow-$1.40M
Total debt$2.42M
Net cash-$2.25M
Altman Z-Score0.76 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+8.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-03-31). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-07-012026-07-02open ↗8-KPeriod ending 2026-06-232026-06-29open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-22open ↗4Period ending 2026-06-152026-06-17open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-012026-05-05open ↗8-KPeriod ending 2026-04-162026-04-16open ↗10-KPeriod ending 2025-12-312026-04-15open ↗8-KPeriod ending 2026-03-312026-04-02open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-242026-03-30open ↗
Frequently asked
- Is Oncotelic Therapeutics, Inc. (OTLC) a buy?
- OTLC currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong net margin (356114.0%); but revenue fell -96.0% YoY.
- What is OTLC's fair value?
- A Modified-Graham model based on OTLC's SEC fundamentals estimates a fair value of about $22.42. It is an estimate from reported earnings, not a price target.
- Is OTLC overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, OTLC currently appears undervalued relative to its SEC-grounded earnings power.
- What is Oncotelic Therapeutics, Inc.'s quality score?
- OTLC scores 60.0876893939394/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000908259, latest 10-Q filed 2026-05-14) · EODHD · as of 6/23/2026, 1:57:48 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 9:57 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.